Cyclacel Pharmaceuticals (CYCC) 10-Q 12 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 11, 2020
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	Cyclacel Pharmaceuticals, Inc.
Entity Central Index Key	0001130166
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,859,998

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 8,923	$ 11,885
Prepaid expenses and other current assets	2,888	2,132
Total current assets	11,811	14,017
Property and equipment, net	25	27
Right-of-use lease asset	1,151	1,264
Total assets	12,987	15,308
Current liabilities:
Accounts payable	250	890
Accrued and other current liabilities	1,273	1,530
Total current liabilities	1,523	2,420
Lease liability	1,073	1,191
Other liabilities
Total liabilities	2,596	3,611
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2019 and March 31, 2020; 859,998 and 859,998 shares issued and outstanding at December 31, 2019 and March 31, 2020.	1	1
Additional paid-in capital	370,183	370,142
Accumulated other comprehensive loss	(946)	(819)
Accumulated deficit	(358,847)	(357,627)
Total stockholders' equity	10,391	11,697
Total liabilities and stockholders' equity	12,987	15,308
6% Convertible Exchangeable Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value
Series A Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	859,998	859,998
Common stock, shares outstanding	859,998	859,998
6% Convertible Exchangeable Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	335,273	335,273
Preferred stock, shares outstanding	335,273	335,273
Dividend rate on convertible exchangeable preferred stock (in percent)	6.00%	6.00%
Preferred stock, liquidation preference value (in dollars)	$ 4,006,512	$ 4,006,512
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued	264	264
Preferred stock, shares outstanding	264	264

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenues
Operating expenses:
Research and development	1,106,000	1,012,000
General and administrative	1,318,000	1,192,000
Total operating expenses	2,424,000	2,204,000
Operating loss	(2,424,000)	(2,204,000)
Other income (expense):
Foreign exchange gains (losses)	69,000	15,000
Interest income	28,000	79,000
Other income, net	817,000
Total other income, net	914,000	94,000
Loss before taxes	(1,510,000)	(2,110,000)
Income tax benefit	290,000	268,000
Net loss	(1,220,000)	(1,842,000)
Dividend on convertible exchangeable preferred shares	(50,000)	(50,000)
Net loss applicable to common shareholders	$ (1,270,000)	$ (1,892,000)
Basic and diluted earnings per common share:
Net loss per share - basic and diluted (in dollars per share)	$ (1.48)	$ (2.77)
Weighted average common shares outstanding - basic and diluted	859,998	681,910
Collaboration and research and development revenue [Member]
Revenues:
Total revenues

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (1,220)	$ (1,842)
Translation adjustment	11,060	(3,897)
Unrealized foreign exchange gain on intercompany loans	(11,187)	3,876
Comprehensive loss	$ (1,347)	$ (1,863)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018		$ 1	$ 365,828	$ (760)	$ (349,797)	$ 15,272
Balance (in shares) at Dec. 31, 2018	335,537	624,872
Issue of common stock on At Market Issuance sales agreement, net of expenses		$ 0	4,111			4,111
Issue of common stock on At Market Issuance sales agreement, net of expenses (in shares)		235,126
Stock-based compensation			85			85
Preferred stock dividends			(50)			(50)
Unrealized foreign exchange on intercompany loans				3,876		3,876
Translation adjustment				(3,897)		(3,897)
Loss for the period					(1,842)	(1,842)
Balance at Mar. 31, 2019		$ 1	369,974	(781)	(351,639)	17,555
Balance (in shares) at Mar. 31, 2019	335,537	859,999
Balance at Dec. 31, 2019		$ 1	370,142	(819)	(357,627)	11,697
Balance (in shares) at Dec. 31, 2019	335,537	859,998
Stock-based compensation			91			91
Preferred stock dividends			(50)			(50)
Unrealized foreign exchange on intercompany loans				(11,187)		(11,187)
Translation adjustment				11,060		11,060
Loss for the period					(1,220)	(1,220)
Balance at Mar. 31, 2020		$ 1	$ 370,183	$ (946)	$ (358,847)	$ 10,391
Balance (in shares) at Mar. 31, 2020	335,537	859,998

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities:
Net loss	$ (1,220)	$ (1,842)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	5	6
Gain on disposal of property and equipment		(29)
Stock-based compensation	91	85
Changes in lease liability	(10)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(874)	(1,215)
Accounts payable and other current liabilities	(799)	(689)
Net cash used in operating activities	(2,807)	(3,684)
Investing activities:
Purchase of property, plant and equipment	(4)	(2)
Proceeds from sale of property and equipment		29
Net cash provided by (used in) investing activities	(4)	27
Financing activities:
Proceeds from issuing common stock, net of issuance costs (Payments of issuance costs)		4,106
Payment of preferred stock dividend	(50)	(50)
Net cash provided by (used in) financing activities	(50)	4,056
Effect of exchange rate changes on cash and cash equivalents	(101)	31
Net (decrease) in cash and cash equivalents	(2,962)	430
Cash and cash equivalents, beginning of period	11,885	17,504
Cash and cash equivalents, end of period	8,923	17,934
Supplemental cash flow information:
Cash received during the period for: Interest	28	79
Cash received during the period for: Taxes
Lease liability		(1,505)
Right-of-use asset		1,385
Non cash financing activities:
Accrual of preferred stock dividends	$ 50	$ 50

Company Overview

Company Overview	3 Months Ended
	Mar. 31, 2020
Company Overview [Abstract]
Company Overview	1. Company Overview Nature of Operations Cyclacel Pharmaceuticals, Inc. (“Cyclacel” or the “Company”) is a clinical-stage biopharmaceutical company using cell cycle control, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel is a pioneer company in the field of cell cycle biology with a vision to improve patient healthcare by translating cancer biology into medicines. As of March 31, 2020, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated balance sheet as of March 31, 2020, the consolidated statements of operations, comprehensive loss, stockholders’ equity and the consolidated statements of cash flows for the three months ended March 31, 2020 and 2019, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2019 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (the “SEC”). The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of March 31, 2020, and the results of operations, comprehensive loss, and cash flows for the three months ended March 31, 2020, have been made. The interim results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2019 that are included in the Company’s Annual Report on Form 10-K filed with the SEC. Reverse Stock Split On April 14, 2020 the Company completed a one-for-twenty reverse stock split, which reduced the number of shares of the Company’s common stock that were issued and outstanding immediately prior to the effectiveness of the reverse stock split. The number of shares of the Company’s authorized common stock was not affected by the reverse stock split and the par value of Cyclacel’s common stock remained unchanged at $0.001 per share. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at April 14, 2020 from 17,199,974 to 859,998 after the cancellation of 14 fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a cash payment in lieu of such fractional shares. All amounts related to number of shares and per share amounts have been retroactively restated in these consolidated financial statements. Going Concern Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern for a period of at least one year from the date the financial statements are issued. The Company expects that its cash of approximately $8.9 million as of March 31, 2020, together with approximately $18.4 million net proceeds received from the sale of securities in April 2020, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2022. This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued, including: a. The Company’s current financial condition, including its sources of liquidity; b. The Company’s conditional and unconditional obligations due or anticipated within one year; c. The funds necessary to maintain the Company’s operations considering its current financial condition, obligations, and other expected cash flows; and d. Other conditions and events that, when considered in conjunction with the above, may adversely affect the Company’s ability to meet its obligations. The future viability of the Company beyond the end of 2022 is dependent on its ability to raise additional capital to finance its operations. The Company does not currently have sufficient funds to complete development and commercialization of any of its drug candidates. Additional funding may not be available to the Company on favorable terms, or at all. If the Company is not able to secure additional funding when needed, it may have to delay, reduce the scope of or eliminate one or more of its clinical trials or research and development programs or make changes to its operating plan. In addition, it may have to partner one or more of its product candidate programs at an earlier stage of development, which would lower the economic value of those programs to the Company. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. Accounting standards adopted in the period On January 1, 2019, the Company adopted the guidance on accounting for leases (“ASC 842”) in Accounting Standards Update No, 2016‑02, Leases, as amended by subsequent updates issued in 2018 and 2019. The guidance requires that lessees recognize both a lease liability, which is a lessee’s obligation to make lease payments arising from a lease measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term at the commencement date. The Company has elected the package of practical expedients permitted in ASC 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease under ASC 842, (b) whether classification of the operating leases would be different in accordance with ASC 842, or (c) whether any unamortized initial direct costs would have met the definition of initial direct costs in ASC 842 at lease commencement. The Company transitioned to the new guidance on a cumulative catch-up basis effective January 1, 2019, recognizing a lease liability of $1.5 million for the present value of the remaining minimum rental payments, as defined under prior accounting rules, and a corresponding right-of-use asset. In addition, the Company reclassified an existing deferred rent obligation of $120,000 created under prior accounting rules against the opening right-of-use asset. On January 1, 2020, the Company adopted the guidance issued in ASU 2018‑15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” As permitted by the ASU, the Company will apply the new guidance on a prospective basis to any new cloud computing arrangements. ASU 2018‑15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the non-cancellable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. There has been no impact of this pronouncement on the Company’s consolidated financial statements and disclosures. Recently Issued Accounting Pronouncements The Financial Accounting Standards Board has issued ASU 2020-04, “Reference Rate Reform (Topic 848)”. This standard provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform initiatives that would replace interbank offered rates, including the London Interbank Offered Rate (LIBOR). For example, modifications of lease contracts within the scope of ASC 842 solely for changes in reference rates would be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate. The amendments in this ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company does not currently have any contracts affected by this guidance. Fair Value of Financial Instruments Financial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities. Comprehensive Income (Loss) All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three months ended March 31, 2019 and 2020. Revenue recognition With effect from January 1, 2018, the Company recognizes revenue using the five step-model provided in ASC 606, Revenue from Contracts with Customers (“ASC 606”): (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the Company satisfies a performance obligation. The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers: · Whether achievement of a development milestone is highly susceptible to factors outside the entity’s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies; · Whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time; · Whether the Company can reasonably predict that the milestone will be achieved based on previous experience; and · The complexity and inherent uncertainty underlying the achievement of the milestone. The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation. The Company recognizes a contract asset, when the value of satisfied (or partially satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable. Grant revenue received from organizations that are not the Company’s customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses. Leases Effective from January 1, 2019, the Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2020, all of the Company’s leases are classified as operating leases. The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company’s obligation to make lease payments under the lease. As the Company’s leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company’s credit risk. The Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as: · The lease payments due in any optional period; · Penalties for failure to exercise (or not exercise) the option; · Market factors, such as the availability of similar assets and current rental rates for such assets; · The nature of the underlying leased asset and its importance to the Company’s operations; and · The remaining useful lives of any related leasehold improvements. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset. The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2020
Revenue Recognition [Abstract]
Revenue	3. Revenue Revenue recognized in the three months ended March 31, 2019 and 2020 was $0.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Net Loss per Share [Abstract]
Net Loss Per Common Share	4. Net Loss per Common Share The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. The following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months ended March 31, 2019 and 2020, as the result would be anti-dilutive: March 31, March 31, 2019 2020 Stock options 112,457 99,957 Convertible preferred stock 85 85 Series A preferred stock 6,600 6,600 Common stock warrants 374,525 374,525 Total shares excluded from calculation 493,667 481,167

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2020
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in $000s): December 31, March 31, 2019 2020 Research and development tax credit receivable $ 1,326 $ 1,525 Prepayments and VAT receivable 703 293 Other current assets 103 1,070 $ 2,132 $ 2,888 Receivables of $817,000 are included in other current assets as at March 31, 2020. This relates to royalty payments receivable under a December 2005 Asset Purchase Agreement, or APA, whereby Xcyte Therapies, Inc., or Xcyte, (a business acquired by the Company in March 2006) sold certain assets and intellectual property to Thermo Fisher Scientific Company, or TSC, (formerly Invitrogen Corporation) through the APA and other related agreements. The assets and technology were not part of the Company’s product development plan following the transaction between Xcyte and Cyclacel in March 2006. Accordingly, the company recognized $817,000 of other income related to this transaction during the three months ended March 31, 2020.

Accrued and Other Liabilities

Accrued and Other Liabilities	3 Months Ended
	Mar. 31, 2020
Payables And Accruals [Abstract]
Accrued and Other Liabilities	6. Accrued and Other Liabilities Accrued and other current liabilities consisted of the following (in $000s): December 31, March 31, 2019 2020 Accrued research and development $ 617 $ 782 Accrued legal and professional fees 235 276 Other current liabilities 678 215 $ 1,530 $ 1,273

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	7. Leases The Company has a single lease related to its facility in Dundee, Scotland. As of and for the three months ended March 31, 2020: The Company recognized operating lease expenses of $76,383. Cash payments made during the three months ended March 31, 2020 totaled $80,739 and were presented as a component of cash outflows from operating activities. The remaining lease term is approximately 5.5 years as of March 31, 2020. The discount rate used by the Company in determining the lease liability was 12%. Remaining lease payments under the lease are: 2020 $ 239 2021 319 2022 318 2023 315 2024 314 Thereafter 252 $ 1,757

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2020
Stock-Based Compensation [Abstract]
Stock Based Compensation	8. Stock Based Compensation ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding) vest ratably over one to four years. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur. Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended March 31, 2019 and 2020 as shown in the following table (in $000s): Three Months Ended March 31, 2019 2020 Research and development $ 31 $ 35 General and administrative 54 56 Stock-based compensation costs before income taxes $ 85 $ 91 2018 Plan In May 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”), under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan replaces the 2015 Equity Incentive Plan (the “2015 Plan”). The 2018 Plan allows for the issuance of up to 75,000 shares of the Company’s common stock pursuant to various types of award grants, including stock options and restricted stock units. In addition, the 2018 Plan allows up to 35,494 additional shares to be issued if awards outstanding under the 2018 Plan are cancelled or expire on or after the date of the Company’s 2018 annual meeting of stockholders. As of March 31, 2020, the Company has reserved 6,822 shares of the Company’s common stock under the 2018 Plan for future issuances, including shares that were available under the 2015 Plan and carried forward to the 2018 Plan. Stock option awards granted under the Company’s equity incentive plans have a maximum life of 10 years and generally vest over a one to four-year period from the date of grant. There were no options granted during the three months ended March 31, 2020. There were 70,951 options granted during the three months ended March 31, 2019. These options had a grant date fair value ranging between $11.40-$12.20 per option. There were also no stock options exercised during each of the three months ended March 31, 2019 and 2020, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises that may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income. Outstanding Options A summary of the share option activity and related information is as follows: Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Per Share Term (Years) Value ($000) Options outstanding at December 31, 2019 100,278 $ 54.40 — $ — Granted — $ — Exercised — Cancelled/forfeited (321) $ 1,063.89 Options outstanding at March 31, 2020 99,957 $ 51.10 8.38 $ — Unvested at March 31, 2020 51,629 $ 14.81 8.81 $ — Vested and exercisable at March 31, 2020 48,328 $ 89.88 7.91 $ — Restricted Stock Units Weighted Number of Average Options Grant Date Outstanding Value Per Share Restricted Stock Units outstanding at December 31, 2019 14,000 $ 10.60 Granted 3,938 $ 15.20 Restricted Stock Units outstanding at March 31, 2020 17,938 $ 11.61 Unvested at March 31, 2020 17,938 $ 11.61 Vested and exercisable at March 31, 2020 — $ —

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity [Abstract]
Stockholders Equity	9. Stockholders Equity October 2018 At Market Issuance On October 4, 2018, the Company entered into a Common Stock Sales Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, as sales agent, pursuant to which Wainwright was authorized to sell shares of common stock, par value $0.001 per share, having an aggregate offering price of up to $5,000,000, by any method that is deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Shares sold under the Sales Agreement were offered and sold pursuant to the Company’s previously filed and effective Registration Statement on Form S‑3 and a prospectus supplement and accompanying base prospectus. The Company paid Wainwright a commission of 3.0% of the gross sales price per share sold. The Sales Agreement was concluded during the first quarter of 2019, pursuant to which the Company sold 235,126 shares for gross proceeds of approximately $4.3 million. Aggregate net proceeds to the Company were approximately $4.7 million, after deducting commissions and other expenses. Warrants As of March 31, 2020, there were 374,525 warrants outstanding, each with an exercise price of $40.00. All such warrants were issued in connection with the July 2017 underwritten public offering and are immediately exercisable. The warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our Common Stock then outstanding after giving effect to such exercise. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such warrant holders are utilizing the cashless exercise provision of the warrants. On the expiration date, unexercised warrants will automatically be exercised via the “cashless” exercise provision. Prior to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein. There was no exercise of warrants during the three months ended March 31, 2019 or 2020. Series A Preferred Stock 8,872 shares of the Company’s Series A Preferred Stock were issued in the July 2017 underwritten public offering. During the year ended December 31, 2017, 8,608 shares of the Series A Preferred Stock were converted into 215,200 shares of common stock. As of March 31, 2020, 264 shares of the Series A Preferred Stock remain issued and outstanding. Each share of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing $1,000 by the initial conversion price of $40.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations. The 264 shares of Series A Preferred Stock issued and outstanding at March 31, 2020, are convertible into 6,600 shares of common stock. In the event of a liquidation, the holders of shares of the Series A Preferred Stock shall be permitted to participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company’s ability to repurchase shares of Series A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and there are no sinking fund provisions applicable to the Series A Preferred Stock. Subject to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder of the Series A Preferred Stock to convert all or part of such holder’s Series A Preferred Stock in the event that (i) the volume weighted average price of our common stock for 30 consecutive trading days (the “Measurement Period”) exceeds 300% of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of the Series A Preferred Stock to convert all or part of such holder’s Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock. The Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions, contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution. 6% Convertible Exchangeable Preferred Stock As of March 31, 2020, there were 335,273 shares of the Company’s 6% Convertible Exchangeable Preferred Stock (the “6% Preferred Stock”) issued and outstanding at an issue price of $10.00 per share. Dividends on the 6% Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the 6% Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company’s board of directors and must come from funds that are legally available for dividend payments. The 6% Preferred Stock has a liquidation preference of $10.00 per share, plus accrued and unpaid dividends. The Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company’s common stock has exceeded $59,220, which is 150% of the conversion price of the 6% Preferred Stock, for at least 20 trading days during any 30‑day trading period, ending within five trading days prior to notice of automatic conversion. The 6% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances. The Company may, at its option, redeem the 6% Preferred Stock in whole or in part, out of funds legally available at the redemption price of $10.00 per share. The 6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November 1, 2005 (the “Exchange Date”) for the Company’s 6% Convertible Subordinated Debentures (the “Debentures”) at the rate of $10.00 principal amount of Debentures for each share of 6% Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have terms substantially similar to those of the 6% Preferred Stock. No such exchanges have taken place to date.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events Dividends on 6% Preferred Stock On March 11, 2020, the board of directors declared a quarterly cash dividend in the amount of $0.15 per share on the Company’s 6% Preferred Stock. The cash dividend was paid on May 1, 2020 to the holders of record of the 6% Preferred Stock as of the close of business on April 15, 2020. Reverse Stock Split On April 14, 2020, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company’s shares of common stock. The reverse stock split, which was unanimously approved by the Company’s board of directors, was approved by the Company’s stockholders at a special meeting of stockholders held on October 28, 2019. As a result of the reverse stock split, every twenty (20) shares of the Company’s outstanding common stock before effectiveness of the reverse stock split was combined and reclassified into one (1) share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. Stockholders who would otherwise hold a fractional share of common stock were entitled to receive payment in cash in lieu of any such resulting fractional shares of common stock as the post-reverse split amounts of common stock were rounded down to the nearest full share. Such cash payment in lieu of a fractional share of common stock was calculated by multiplying such fractional interest in one share of common stock by the closing trading price of the Company’s common stock on the trading day immediately preceding the effective date of the reverse stock split, and rounded to the nearest cent. No fractional shares were issued in connection with the reverse stock split. All share and per share figures in these unaudited consolidated financial statements have been retrospectively restated to give effect to the reverse stock split. Coronavirus Outbreak In December 2019, a novel strain of coronavirus emerged in Wuhan, Hubei Province, China. It has now spread to many other countries, including the United States and United Kingdom, where the Company has its primary bases of operation. The World Health Organization has declared the coronavirus outbreak a pandemic, and many governments have issued “stay at home” orders for the foreseeable future. The extent to which the coronavirus impacts the Company’s financial condition and operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, any new information that may emerge concerning the severity of the coronavirus, and the actions taken to contain the coronavirus or treat its impact, among others. At this time, the Company is unable to estimate the impact of this event on its financial condition or operations, but it could materially affect the ability of the Company to raise future capital or to conduct clinical studies on a timely basis. Material Transfer Agreement On April 19, 2020, the Company entered into a Material Transfer Agreement (“MTA”) with The University of Edinburgh (the “University”). The main objective of the MTA is to study fadraciclib and seliciclib (CYC202 or R-roscovitine), the Company’s clinical stage CDK2/9 inhibitors, as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. Under the terms of the MTA, the parties will assess the Company’s medicines mentioned above for their suitability for use in safety and experimental medicine studies in COVID-19 patients (the “Evaluation”). The Evaluation is part of a broader project (“STOPCOVID”) studying the inflammatory pathways that lead directly to COVID-19 lung injury. STOPCOVID is supported by a £2 million (approximately $2.5 million) grant from LifeArc, a medical research charity. The University is seeking further funding. The MTA shall remain in effect for the duration of the Evaluation. Additionally, each of the Company and the University may terminate the MTA if the other party commits a breach of its obligations thereunder. April 2020 equity financing On April 21, 2020, the Company entered into a co-placement agency agreement with Roth Capital Partners, LLC, Ladenburg Thalmann & Co. Inc., and Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Co-Placement Agents”) and a securities purchase agreement with certain purchasers for the purchase and sale of (i) 1,910,000 shares of common stock, (ii) pre-funded warrants to purchase up to 2,090,000 shares of common stock, and (iii) accompanying common stock warrants to purchase up to 4,000,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined public offering price of $5.00 per share and common stock warrant. Each common stock warrant sold with the shares of common stock represents the right to purchase one share of common stock at an exercise price of $5.00 per share. The common stock warrants are exercisable immediately and expire five years from the date of issuance. The pre-funded warrants and accompanying common stock warrants were sold at a combined public offering price of $4.999 per pre-funded warrant and common stock warrant. The pre-funded warrants were sold to purchasers whose purchase of shares of common stock in the public offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of the Company’s outstanding common stock immediately following the consummation of the public offering, in lieu of shares of common stock. Each pre-funded warrant represents the right to purchase one share of the Company’s common stock at an exercise price of $0.001 per share. The pre-funded warrants are exercisable immediately and may be exercised at any time until the pre-funded warrants are exercised in full. The shares of common stock and pre-funded warrants, and accompanying common stock warrants, were issued separately and are immediately separable upon issuance. The closing of the offering occurred on April 24, 2020, and the net proceeds to the Company were approximately $18,400,000 after deducting placement agent fees and other offering expenses payable by the Company. Subsequent to the closing of the offering, all the 2,090,000 pre-funded warrants were converted into 2,090,000 shares of common stock. Following such conversions, 4,859,998 shares of common stock remain outstanding as of May 11, 2020. Nasdaq Listing Compliance On April 29, 2020, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has evidenced full compliance with all criteria for continued listing on Nasdaq, including the $1.00 minimum bid, as required by Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). As previously disclosed, on March 27, 2020, the Nasdaq Listing Qualifications Panel (the “Panel”) granted the Company’s request for continued listing on Nasdaq pursuant to an extension through June 12, 2020, to regain compliance with the Bid Price Rule by evidence of a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. On April 14, 2020, the Company implemented a one-for-twenty reverse stock split of the Company’s outstanding common stock and, as of the close of business on April 28, 2020, evidenced compliance with the Bid Price Rule. That matter is now closed.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated balance sheet as of March 31, 2020, the consolidated statements of operations, comprehensive loss, stockholders’ equity and the consolidated statements of cash flows for the three months ended March 31, 2020 and 2019, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2019 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (the “SEC”). The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of March 31, 2020, and the results of operations, comprehensive loss, and cash flows for the three months ended March 31, 2020, have been made. The interim results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2019 that are included in the Company’s Annual Report on Form 10-K filed with the SEC.
Reverse Stock Split	Reverse Stock Split On April 14, 2020 the Company completed a one-for-twenty reverse stock split, which reduced the number of shares of the Company’s common stock that were issued and outstanding immediately prior to the effectiveness of the reverse stock split. The number of shares of the Company’s authorized common stock was not affected by the reverse stock split and the par value of Cyclacel’s common stock remained unchanged at $0.001 per share. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at April 14, 2020 from 17,199,974 to 859,998 after the cancellation of 14 fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a cash payment in lieu of such fractional shares. All amounts related to number of shares and per share amounts have been retroactively restated in these consolidated financial statements.
Going Concern	Going Concern Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern for a period of at least one year from the date the financial statements are issued. The Company expects that its cash of approximately $8.9 million as of March 31, 2020, together with approximately $18.4 million net proceeds received from the sale of securities in April 2020, will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2022. This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued, including: a. The Company’s current financial condition, including its sources of liquidity; b. The Company’s conditional and unconditional obligations due or anticipated within one year; c. The funds necessary to maintain the Company’s operations considering its current financial condition, obligations, and other expected cash flows; and d. Other conditions and events that, when considered in conjunction with the above, may adversely affect the Company’s ability to meet its obligations. The future viability of the Company beyond the end of 2022 is dependent on its ability to raise additional capital to finance its operations. The Company does not currently have sufficient funds to complete development and commercialization of any of its drug candidates. Additional funding may not be available to the Company on favorable terms, or at all. If the Company is not able to secure additional funding when needed, it may have to delay, reduce the scope of or eliminate one or more of its clinical trials or research and development programs or make changes to its operating plan. In addition, it may have to partner one or more of its product candidate programs at an earlier stage of development, which would lower the economic value of those programs to the Company. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.
Accounting Standards Adopted in the Period	Accounting standards adopted in the period On January 1, 2019, the Company adopted the guidance on accounting for leases (“ASC 842”) in Accounting Standards Update No, 2016‑02, Leases, as amended by subsequent updates issued in 2018 and 2019. The guidance requires that lessees recognize both a lease liability, which is a lessee’s obligation to make lease payments arising from a lease measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term at the commencement date. The Company has elected the package of practical expedients permitted in ASC 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease under ASC 842, (b) whether classification of the operating leases would be different in accordance with ASC 842, or (c) whether any unamortized initial direct costs would have met the definition of initial direct costs in ASC 842 at lease commencement. The Company transitioned to the new guidance on a cumulative catch-up basis effective January 1, 2019, recognizing a lease liability of $1.5 million for the present value of the remaining minimum rental payments, as defined under prior accounting rules, and a corresponding right-of-use asset. In addition, the Company reclassified an existing deferred rent obligation of $120,000 created under prior accounting rules against the opening right-of-use asset. On January 1, 2020, the Company adopted the guidance issued in ASU 2018‑15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” As permitted by the ASU, the Company will apply the new guidance on a prospective basis to any new cloud computing arrangements. ASU 2018‑15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the non-cancellable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. There has been no impact of this pronouncement on the Company’s consolidated financial statements and disclosures. Recently Issued Accounting Pronouncements The Financial Accounting Standards Board has issued ASU 2020-04, “Reference Rate Reform (Topic 848)”. This standard provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform initiatives that would replace interbank offered rates, including the London Interbank Offered Rate (LIBOR). For example, modifications of lease contracts within the scope of ASC 842 solely for changes in reference rates would be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate. The amendments in this ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company does not currently have any contracts affected by this guidance.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts, notably their short maturities.
Comprehensive Income (Loss)	Comprehensive Income (Loss) All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three months ended March 31, 2019 and 2020.
Revenue Recognition	Revenue recognition With effect from January 1, 2018, the Company recognizes revenue using the five step-model provided in ASC 606, Revenue from Contracts with Customers (“ASC 606”): (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the Company satisfies a performance obligation. The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers: · Whether achievement of a development milestone is highly susceptible to factors outside the entity’s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies; · Whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time; · Whether the Company can reasonably predict that the milestone will be achieved based on previous experience; and · The complexity and inherent uncertainty underlying the achievement of the milestone. The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation. The Company recognizes a contract asset, when the value of satisfied (or partially satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable. Grant revenue received from organizations that are not the Company’s customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses.
Leases	Leases Effective from January 1, 2019, the Company accounts for lease contracts in accordance with ASC 842. As of March 31, 2020, all of the Company’s leases are classified as operating leases. The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company’s obligation to make lease payments under the lease. As the Company’s leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company’s credit risk. The Company evaluates options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as: · The lease payments due in any optional period; · Penalties for failure to exercise (or not exercise) the option; · Market factors, such as the availability of similar assets and current rental rates for such assets; · The nature of the underlying leased asset and its importance to the Company’s operations; and · The remaining useful lives of any related leasehold improvements. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset. The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2020
Net Loss per Share [Abstract]
Schedule of Company's Potential Anti-dilutive Securities	March 31, March 31, 2019 2020 Stock options 112,457 99,957 Convertible preferred stock 85 85 Series A preferred stock 6,600 6,600 Common stock warrants 374,525 374,525 Total shares excluded from calculation 493,667 481,167

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Prepaid Expenses And Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in $000s): December 31, March 31, 2019 2020 Research and development tax credit receivable $ 1,326 $ 1,525 Prepayments and VAT receivable 703 293 Other current assets 103 1,070 $ 2,132 $ 2,888

Accrued and Other Liabilities (

Accrued and Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities consisted of the following (in $000s): December 31, March 31, 2019 2020 Accrued research and development $ 617 $ 782 Accrued legal and professional fees 235 276 Other current liabilities 678 215 $ 1,530 $ 1,273

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases	Remaining lease payments under the lease are: 2020 $ 239 2021 319 2022 318 2023 315 2024 314 Thereafter 252 $ 1,757

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Stock-Based Compensation [Abstract]
Schedule of Stock Based Compensation Expense	Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three months ended March 31, 2019 and 2020 as shown in the following table (in $000s): Three Months Ended March 31, 2019 2020 Research and development $ 31 $ 35 General and administrative 54 56 Stock-based compensation costs before income taxes $ 85 $ 91
Schedule of Share Option Activity	Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Per Share Term (Years) Value ($000) Options outstanding at December 31, 2019 100,278 $ 54.40 — $ — Granted — $ — Exercised — Cancelled/forfeited (321) $ 1,063.89 Options outstanding at March 31, 2020 99,957 $ 51.10 8.38 $ — Unvested at March 31, 2020 51,629 $ 14.81 8.81 $ — Vested and exercisable at March 31, 2020 48,328 $ 89.88 7.91 $ —
Schedule of Restricted Stock Units Activity	Restricted Stock Units Weighted Number of Average Options Grant Date Outstanding Value Per Share Restricted Stock Units outstanding at December 31, 2019 14,000 $ 10.60 Granted 3,938 $ 15.20 Restricted Stock Units outstanding at March 31, 2020 17,938 $ 11.61 Unvested at March 31, 2020 17,938 $ 11.61 Vested and exercisable at March 31, 2020 — $ —

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Narrative) (Details)	Apr. 24, 2020USD ($)	Apr. 24, 2020USD ($)	Apr. 14, 2020$ / sharesshares	Apr. 13, 2020shares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)shares	Jan. 01, 2020USD ($)	Dec. 31, 2019USD ($)$ / shares
Accounting Policies [Line Items]
Right-of-use lease asset					$ 1,151,000			$ 1,264,000
Deferred rent obligation							$ 120,000
Cash and cash equivalents					8,923,000			11,885,000
Lease liability					$ 1,073,000		$ 1,500,000	$ 1,191,000
Common stock, par value (in dollars per share) | $ / shares					$ 0.001			$ 0.001
Weighted average common shares outstanding (in shares) | shares					859,998	681,910
Tax on other comprehensive income (loss)					$ 0
Reclassifications out of other comprehensive income (loss)					$ 0	$ 0
Lease, practical expedients package					true
Subsequent Events [Member]
Accounting Policies [Line Items]
Net proceeds from equity financing	$ 18,400,000	$ 18,400,000
Stockholders' equity, reverse stock split			On April 14, 2020, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company's shares of common stock.
Reverse stock split ratio			0.05
Common stock, par value (in dollars per share) | $ / shares			$ 0.001
Weighted average common shares outstanding (in shares) | shares			859,998	17,199,974
Reverse stock split, Number of fractional shares cancelled | shares			14
Reverse stock split, fractional shares issued | shares			0

Revenue (Narrative) (Details)

Revenue (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue Recognition [Abstract]
Revenue

Net Loss per Common Share (Sche

Net Loss per Common Share (Schedule of Company's Potential Anti Dilutive Securities) (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	481,167	493,667
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	99,957	112,457
6% Convertible Exchangeable Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	85	85
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	6,600	6,600
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from calculation	374,525	374,525

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Other current assets	$ 1,070,000	$ 103,000
Other income, net	817,000
Accounts Receivable [Member]
Other current assets	$ 817,000

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Research and development tax credit receivable	$ 1,525	$ 1,326
Prepayments and VAT receivable	293	703
Other current assets	1,070	103
Prepaid expenses and other current assets	$ 2,888	$ 2,132

Accrued and Other Liabilities_2

Accrued and Other Liabilities (Schedule of accrued and other current liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued research and development	$ 782	$ 617
Accrued legal and professional fees	276	235
Other current liabilities	215	678
Accrued and other current liabilities	$ 1,273	$ 1,530

Leases (Narrative) (Details)

Leases (Narrative) (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Operating lease expense	$ 76,383
Operating lease, payments	$ 80,739
Remaining lease term	5 years 6 months
Discount rate lease liability	12.00%

Leases (Future Minimum Lease Pa

Leases (Future Minimum Lease Payments) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Operating Lease Obligation
2020	$ 239
2021	319
2022	318
2023	315
2024	314
Thereafter	252
Lease payments, Total	$ 1,757

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restricted Stock Units (RSUs) [Member]
Stock-based compensation
Restricted Stock Units outstanding	3,938
2018 Equity Incentive Plan (the "2018 Plan") [Member]
Stock-based compensation
Number of authorized shares	75,000
Number of additional shares authorized	35,494
Number of shares reserved for issuance	6,822
2018 Equity Incentive Plan (the "2018 Plan") [Member] | Minimum [Member]
Stock-based compensation
Stock awards vesting period	1 year
2018 Equity Incentive Plan (the "2018 Plan") [Member] | Maximum [Member]
Stock-based compensation
Stock awards vesting period	4 years
2018 Equity Incentive Plan (the "2018 Plan") [Member] | Stock Options [Member]
Stock-based compensation
Life of stock option awards granted	10 years
Options granted (in shares)	0	70,951
Stock option exercised (in shares)	0	0
2018 Equity Incentive Plan (the "2018 Plan") [Member] | Stock Options [Member] | Minimum [Member]
Stock-based compensation
Options granted, grant date fair value		$ 11.40
Stock awards vesting period	1 year
2018 Equity Incentive Plan (the "2018 Plan") [Member] | Stock Options [Member] | Maximum [Member]
Stock-based compensation
Options granted, grant date fair value		$ 12.20
Stock awards vesting period	4 years

Stock Based Compensation (Sched

Stock Based Compensation (Schedule of Stock Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs before income taxes	$ 91	$ 85
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs before income taxes	35	31
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs before income taxes	$ 56	$ 54

Stock-Based Compensation (Sched

Stock-Based Compensation (Schedule of Share Option Activity) (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Options Outstanding
Options outstanding | shares	100,278
Cancelled/forfeited | shares	(321)
Options outstanding | shares	99,957
Unvested | shares	51,629
Vested and exercisable | shares	48,328
Weighted Average Exercise Price Per Share
Options outstanding | $ / shares	$ 54.40
Cancelled/forfeited (in dollars per share) | $ / shares	1,063.89
Options outstanding | $ / shares	51.10
Unvested | $ / shares	14.81
Vested and exercisable | $ / shares	$ 89.88
Weighted Average Remaining Contractual Term (Years)
Options outstanding	8 years 4 months 17 days
Unvested	8 years 9 months 22 days
Vested and exercisable	7 years 10 months 28 days

Stock Based Compensation (Sch_2

Stock Based Compensation (Schedule of Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance | shares	14,000
Weighted average grant date fair value, beginning balance | $ / shares	$ 10.60
Granted | shares	3,938
Granted, weighted average grant date fair value | $ / shares	$ 15.20
Ending Balance | shares	17,938
Weighted average grant date fair value, ending balance | $ / shares	$ 11.61
Unvested | shares	17,938
Unvested, weighted average grant date fair value | $ / shares	$ 11.61
Vested and exercisable | shares
Vested and exercisable, weighted average grant date fair value | $ / shares

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	Mar. 11, 2020	Oct. 04, 2018	Jul. 31, 2017	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2017
Class of Stock [Line Items]
Common stock, par value (in dollars per share)				$ 0.001			$ 0.001
Proceeds from issuance of common stock, net of issuance costs						$ 4,106,000
Proceeds from further issuance of share						4,111,000
Common Stock [Member]
Class of Stock [Line Items]
Proceeds from further issuance of share						$ 0
Number of shares issued (in shares)						235,126
Common Stock Sales Agreement [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.001
Proceeds from issuance of common stock, gross					$ 4,300,000
Proceeds from issuance of common stock, net of issuance costs					$ 4,700,000
Selling commissions, percentage		3.00%
Number of share sold under the sales agreement					235,126
Maximum [Member] | Common Stock Sales Agreement [Member]
Class of Stock [Line Items]
Aggregate offering price		$ 5,000,000
Warrant [Member]
Class of Stock [Line Items]
Conversion percentage				9.99%
Number of warrants outstanding				$ 374,525
Warrants, exercise price per share				$ 40
Warrants, expiration date				Dec. 31, 2024
Percentage of blocker provision				4.99%
Proceeds from warrants exercised				$ 0		$ 0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued			8,872	264			264
Preferred stock, shares outstanding				264			264
Preferred stock, par value (in dollars per share)				$ 0.001			$ 0.001
Number of common shares issued upon conversion								215,200
Number of shares converted				6,600				8,608
Price per share used to determine number of shares of common stock			$ 1,000
Conversion price of convertible preferred stock			$ 40
Conversion percentage			9.99%
Measurement period of consecutive trading days used in determining whether specified triggers are met which would allow the entity to require the conversion of all or part of outstanding preferred stock				30 days
Percentage of blocker provision			4.99%
Series A Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Percentage by which the weighted average price of common stock during the measurement period exceeds the initial conversion price which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted				300.00%
Threshold amount of daily trading volume on each trading day during the measurement period which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted				$ 500,000
6% Convertible Exchangeable Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued				335,273			335,273
Preferred stock, shares outstanding				335,273			335,273
Preferred stock, par value (in dollars per share)				$ 0.001			$ 0.001
Dividend rate on convertible exchangeable preferred stock (in percent)				6.00%			6.00%
Share issue price per share				$ 10
Liquidation preference (in dollars per share)				10
Share Price				$ 59,220
Percentage of closing sales price of common stock that conversion price must exceed in order for preferred stock to be convertible				150.00%
Number of trading days prior to notice of automatic conversion				5 days
Interest rate of Convertible Subordinated Debentures (as a percent)				6.00%
Redemption price per share (in dollars per share)				$ 10
Debt principal amount per share, basis for exchange (in dollars per share)				$ 10
Debt instrument, term				25 years
Preferred stock dividend declared, amount per share	$ 0.15
6% Convertible Exchangeable Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Number of trading days within 30 trading days in which the closing price of common stock must exceed conversion price for preferred stock to be convertible				20 days

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) $ / shares in Units, £ in Millions

May 01, 2020

Apr. 24, 2020USD ($)

Apr. 24, 2020USD ($)shares

Apr. 21, 2020$ / sharesshares

Apr. 19, 2020GBP (£)

Apr. 19, 2020USD ($)

Apr. 15, 2020

Apr. 14, 2020shares

Mar. 11, 2020

Jul. 31, 2017

Mar. 31, 2020$ / sharesshares

Dec. 31, 2019shares

May 11, 2020shares

Subsequent Event [Line Items]

Entity Common Stock, Shares Outstanding

4,859,998

Common stock, shares outstanding

859,998

859,998

Co-Placement Agents and Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Percentage of outstanding common stock

9.99%

Subsequent Events [Member]

Subsequent Event [Line Items]

Stockholders' equity, reverse stock split

On April 14, 2020, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of the Company's shares of common stock.

Reverse stock split ratio

0.05

Fractional shares issued

0

Pre-funded warrants converted into shares

2,090,000

Net proceeds from equity financing | $

$ 18,400,000

$ 18,400,000

Subsequent Events [Member] | MTA [Member]

Subsequent Event [Line Items]

Grant from LifeAr

£ 2

$ 2,500,000

Subsequent Events [Member] | Co-Placement Agents and Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Number of shares issued (in shares)

1,910,000

Combined offering price (in dollars per share) | $ / shares

$ 5

Number of common shares

1

Warrants, exercise price per share | $ / shares

$ 5

Warrant expiry term

5 years

Subsequent Events [Member] | Co-Placement Agents and Securities Purchase Agreement [Member] | Election of the Purchaser [Member]

Subsequent Event [Line Items]

Percentage of outstanding common stock

9.99%

Maximum [Member] | Subsequent Events [Member] | Co-Placement Agents and Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Pre-funded warrants to purchase common shares

2,090,000

Warrants to purchase shares

4,000,000

Warrant [Member]

Subsequent Event [Line Items]

Percentage of blocker provision

4.99%

Conversion percentage

9.99%

Warrants, exercise price per share | $ / shares

$ 40

Warrant [Member] | Subsequent Events [Member] | Co-Placement Agents and Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Percentage of blocker provision

4.999%

Prefunded warrant exercise price | $ / shares

$ 0.001

Warrant [Member] | Minimum [Member] | Subsequent Events [Member] | Co-Placement Agents and Securities Purchase Agreement [Member] | Beneficially Owning [Member]

Subsequent Event [Line Items]

Conversion percentage

4.99%

Series A Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Percentage of blocker provision

4.99%

Conversion percentage

9.99%

6% Convertible Exchangeable Preferred Stock [Member]

Subsequent Event [Line Items]

Dividend declared, date

Mar. 11, 2020

Dividend rate on convertible exchangeable preferred stock (in percent)

6.00%

6.00%

Combined offering price (in dollars per share) | $ / shares

$ 59,220

6% Convertible Exchangeable Preferred Stock [Member] | Subsequent Events [Member]

Subsequent Event [Line Items]

Dividends payable, date to be paid

May 1, 2020

Dividend, record date

Apr. 15, 2020